{"name":"2cc5d08d-2f3e-41a8-b3e0-5f741c79e73c","sections":[{"uuid":"0c900a99-4647-43a9-b563-3ba74bc59277","position":1,"styles":{"offsetDifference":0,"offsetTop":15,"offsetBottom":15,"containerWidth":1200},"gridGap":15,"container":1200,"hidden":false,"columns":[{"uuid":"b9edd9f4-f5b2-4f51-bafb-919920e46cc2","blocks":[{"uuid":"085f7e6c-fcf2-477e-b17a-3224a6ae213e","styles":{},"content":{"html":"

Effective 23.06.2025 the following information on the below qualified investments will be amended:

\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n

\n \n	\n Issuer’s Full Name \n
\n Identification code \n	\n ISIN \n	\n Prior to 23.06.2025 \n	\n As of 23.06.2025 \n
\n OCX \n	\n US68235C2061 \n	\n Oncocyte Corporation \n	\n Insight Molecular Diagnostics Inc. \n
\n \n	\n Trading Symbol \n
\n Identification code \n	\n ISIN \n	\n Prior to 23.06.2025 \n	\n As of 23.06.2025 \n
\n OCX \n	\n US68235C2061 \n	\n OCX \n	\n IMDX \n

"},"icon":{"key":null,"ref":null,"props":{},"_owner":null},"activeDefault":true,"eventKeyCodeExceptions":[46],"type":"NewEditor","name":"Editor"}],"width":12,"connector":false,"position":1}],"containerOffset":0}],"selection":[{"uuid":"085f7e6c-fcf2-477e-b17a-3224a6ae213e","styles":{},"content":{"html":"

Effective 23.06.2025 the following information on the below qualified investments will be amended:

\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n

\n \n	\n Issuer’s Full Name \n
\n Identification code \n	\n ISIN \n	\n Prior to 23.06.2025 \n	\n As of 23.06.2025 \n
\n OCX \n	\n US68235C2061 \n	\n Oncocyte Corporation \n	\n Insight Molecular Diagnostics Inc. \n
\n \n	\n Trading Symbol \n
\n Identification code \n	\n ISIN \n	\n Prior to 23.06.2025 \n	\n As of 23.06.2025 \n
\n OCX \n	\n US68235C2061 \n	\n OCX \n	\n IMDX \n

"},"icon":{"key":null,"ref":null,"props":{},"_owner":null},"activeDefault":true,"eventKeyCodeExceptions":[46],"type":"NewEditor","name":"Editor"}]}

On amending the information in respect of ordinary shares of Oncocyte Corporation (OCX)